OmniaBio, a subsidiary of CCRM, has made an acquisition agreement with Medipost, a global company in stem cell therapeutics. Medipost is acquiring an interest in OmniaBio from CCRM for cash of $30 million and is investing an additional $60 million into OmniaBio. “CCRM has spent a great deal of time looking for the right investment partner for OmniaBio, and we are very pleased to have Medipost on board,” said Mitchel Sivilotti, president of OmniaBio. “Medipost will be an initial anchor and rev...